Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other research analysts have also recently commented on the company. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. HC Wainwright increased their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Wolfe Research began coverage on Dianthus Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $98.00 target price on the stock. Truist Financial increased their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Stock Up 1.6%

DNTH opened at $86.84 on Friday. The stock has a market cap of $4.75 billion, a PE ratio of -21.03 and a beta of 1.18. Dianthus Therapeutics has a 52 week low of $16.64 and a 52 week high of $96.50. The business’s fifty day simple moving average is $81.01 and its 200 day simple moving average is $56.30.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, equities analysts anticipate that Dianthus Therapeutics will post -3.91 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $3,559,646.18. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,021 shares of company stock valued at $26,564,008 over the last three months. 3.02% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its holdings in shares of Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares during the period. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth about $32,000. Virtus Investment Advisers LLC boosted its holdings in shares of Dianthus Therapeutics by 7.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares during the period. Parkside Financial Bank & Trust boosted its holdings in shares of Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the period. Finally, Royal Bank of Canada boosted its holdings in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after purchasing an additional 542 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Dianthus Therapeutics and set a $130 price target, suggesting meaningful upside from current levels.
• Positive Sentiment: The firm raised several earnings estimates for Dianthus Therapeutics, including FY2026 EPS to ($4.81) from ($6.21) and FY2027 EPS to ($5.49) from ($6.04), which may be viewed as improved outlook revisions.
• Neutral Sentiment: HC Wainwright also updated quarterly EPS forecasts for Q2 2026, Q3 2026, Q4 2026, and multiple 2027 quarters, but these remain negative EPS estimates as the company is still expected to be unprofitable.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.